# Olon

a biopharmaceutical CDMO that in October 2025 announced a partnership with Ajinomoto Bio-Pharma Services, strengthening European cGMP fermentation and API capacity for steroid and other complex APIs.

Source: https://en.bioecon.ru/companies/olon/
Updated: 2026-07-20

- Country: Italy

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | €25 million non-convertible notes issued via US private placement, with an associated US$200 million shelf facility | https://www.whitecase.com/news/press-release/white-case-advises-olon-eu25-million-us-private-placement-and-us200-million |
| Capacity | Total fermentation capacity of 5,000 m3 | https://olonspa.com/cdmo/, https://olonspa.com/news/olon-ajinomoto-bio-pharma-services-partnership/, https://olonspa.com/technologies/, https://olonspa.com/wp-content/uploads/2026/03/OLON_2025_REPORT-EN_INTERNO_ESEC_WEB.pdf, https://pharmasource.global/content/news/cdmo-news/ajinomoto-bio-pharma-services-and-olon-partner-to-scale-sustainable-biologics-manufacturing/ |
| Certification | ISO 14001, ISO 45001, cGMP, and GFSI (FSSC 22000) compliant; production sites in Capua, Garessio, Settimo Torinese, Mahad, and Derivados Químicos are ISO 14001 certified | https://olonspa.com/news/focus/to-make-the-bioeconomy-real-develop-for-scalability-and-creditworthiness/, https://olonspa.com/wp-content/uploads/2026/03/OLON_2025_REPORT-EN_INTERNO_ESEC_WEB.pdf |
| Regulatory approval | Olon API India Pvt. Ltd. (Mahad site) confirmed operating at an acceptable level of compliance with WHO GMP Guidelines for APIs as of September 2025 | https://extranet.who.int/prequal/sites/default/files/whopir_files/WHOPIR_Olon2-5September2025.pdf |
| Production site | 14 manufacturing sites worldwide (9 in Italy, 2 in France, 1 in Spain, 1 in the United States, 1 in India) | https://olonspa.com/news/olon-ajinomoto-bio-pharma-services-partnership/, https://olonspa.com/wp-content/uploads/2026/03/OLON_2025_REPORT-EN_INTERNO_ESEC_WEB.pdf |
| Headcount | Over 2,800 employees | https://extranet.who.int/prequal/sites/default/files/whopir_files/WHOPIR_Olon2-5September2025.pdf, https://olonspa.com/news/olon-ajinomoto-bio-pharma-services-partnership/, https://olonspa.com/wp-content/uploads/2026/03/OLON_2025_REPORT-EN_INTERNO_ESEC_WEB.pdf |
| Revenue | €615 million for the full year 2024 | https://olonspa.com/wp-content/uploads/2026/03/OLON_2025_REPORT-EN_INTERNO_ESEC_WEB.pdf |

Independent sources: extranet.who.int, pharmasource.global, whitecase.com

## Technologies

- [Biosynthetic steroids (fermentation & biocatalytic API)](https://en.bioecon.ru/technology/biosynthetic-steroids/)